ProCE Banner Activity

Indolent B-Cell Lymphomas: Clinical Application of New Advances in Community Practice

Slideset Download
Download this slideset from a local live webinar to learn how to optimally manage your patients with indolent lymphomas.

Released: June 21, 2022

Expiration: June 20, 2023

No longer available for credit.

Share

Faculty

Elizabeth Brém

Elizabeth Brém, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
School of Medicine
University of California Irvine Medical Center
Orange, California

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Bristol Myers Squibb

Incyte Corporation

Faculty Disclosure

Primary Author

Elizabeth Brém, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
School of Medicine
University of California Irvine Medical Center
Orange, California

Elizabeth Brém, MD, has disclosed that she has received consulting fees from Acrotech Biopharma and TG Therapeutics, is on the ad board for ADC Therapeutics and Kite, is on the speaker’s bureau for SeaGen, and is on the ad board and speaker’s bureau for BeiGene, Incyte, Janssen, MorphoSys, and Pharmacyclics.

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS, has disclosed that he has received consultant fees from AstraZeneca, Bayer, BeiGene, Bioscend, BMS, Celgene, Curio Sciences, Denovo Biopharma, Epizyme/Incyte, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys AG, Pharmacyclics/Janssen, and SeaGen and has received research funding from 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Genentech/Roche, Gilead, Guardant, Iovance, Janssen, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, and Ziopharm.